Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


30.10.2017

1 Ann Hematol
1 Biochem Pharmacol
3 Blood
1 Br J Cancer
2 Cancer
1 Eur J Haematol
2 Exp Hematol
2 Leuk Lymphoma
14 Leukemia
3 Oncogene
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Hematol

  1. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Text format     Abstract available


    Biochem Pharmacol

  2. HAMDOUN S, Fleischer E, Klinger A, Efferth T, et al
    Lawsone derivatives target the Wnt/beta-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells.
    Biochem Pharmacol. 2017 Oct 20. pii: S0006-2952(17)30638.
    PubMed     Text format     Abstract available


    Blood

  3. GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
    AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
    Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
    PubMed     Text format     Abstract available

  4. KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
    Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Blood. 2017;130:1585-1596.
    PubMed     Text format     Abstract available

  5. JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
    Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Blood. 2017;130:1514-1522.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. CASSIER PA, Castets M, Belhabri A, Vey N, et al
    Targeting apoptosis in acute myeloid leukaemia.
    Br J Cancer. 2017;117:1089-1098.
    PubMed     Text format     Abstract available


    Cancer


  7. First Person: Clara Bloomfield, MD.
    Cancer. 2017;123:369-370.
    PubMed     Text format    

  8. PRINTZ C
    Device rapidly measures cell growth and can help determine drug resistance in cancer.
    Cancer. 2017;123:10-11.
    PubMed     Text format    


    Eur J Haematol

  9. GONSALVES WI, Buadi FK, Kumar SK
    Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12986.
    PubMed     Text format     Abstract available


    Exp Hematol

  10. KIM YM, Gang EJ, Kahn M
    CBP/Catenin antagonists: Targeting LSCs' Achilles heel.
    Exp Hematol. 2017;52:1-11.
    PubMed     Text format     Abstract available

  11. HEROLD N, Rudd SG, Sanjiv K, Kutzner J, et al
    With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
    Exp Hematol. 2017;52:32-39.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  12. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Text format     Abstract available

  13. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Text format     Abstract available


    Leukemia

  14. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
    Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Leukemia. 2017;31:1788-1797.
    PubMed     Text format     Abstract available

  15. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
    IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
    Leukemia. 2017;31:1686-1694.
    PubMed     Text format     Abstract available

  16. YAN F, Shen N, Pang JX, Zhang YW, et al
    Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
    Leukemia. 2017;31:1434-1442.
    PubMed     Text format     Abstract available

  17. CHENG G, Liu F, Asai T, Lai F, et al
    Loss of p300 accelerates MDS-associated leukemogenesis.
    Leukemia. 2017;31:1382-1390.
    PubMed     Text format     Abstract available

  18. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
    In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
    Leukemia. 2017;31:1398-1407.
    PubMed     Text format     Abstract available

  19. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
    PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
    Leukemia. 2017;31:1423-1433.
    PubMed     Text format     Abstract available

  20. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
    Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Leukemia. 2017;31:1340-1347.
    PubMed     Text format     Abstract available

  21. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available

  22. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
    Leukemia. 2017;31:829-836.
    PubMed     Text format     Abstract available

  23. DUELL J, Dittrich M, Bedke T, Mueller T, et al
    Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Leukemia. 2017;31:2181-2190.
    PubMed     Text format     Abstract available

  24. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
    Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
    Leukemia. 2017;31:1408-1414.
    PubMed     Text format     Abstract available

  25. JU HQ, Zhan G, Huang A, Sun Y, et al
    ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia. 2017;31:2143-2150.
    PubMed     Text format     Abstract available

  26. MUNIR T, Howard DR, McParland L, Pocock C, et al
    Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia. 2017;31:2085-2093.
    PubMed     Text format     Abstract available

  27. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
    APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Leukemia. 2017;31:2057-2064.
    PubMed     Text format     Abstract available


    Oncogene

  28. TSURUTA-KISHINO T, Koya J, Kataoka K, Narukawa K, et al
    Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Oncogene. 2017;36:3300-3311.
    PubMed     Text format     Abstract available

  29. ABBACI A, Talbot H, Saada S, Gachard N, et al
    Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  30. HEYDT Q, Larrue C, Saland E, Bertoli S, et al
    Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    PLoS One

  31. TAVERNA L, Tremolada M, Bonichini S, Tosetto B, et al
    Motor skill delays in pre-school children with leukemia one year after treatment: Hematopoietic stem cell transplantation therapy as an important risk factor.
    PLoS One. 2017;12:e0186787.
    PubMed     Text format     Abstract available

  32. ZHANG P, Zhao X, Zhang W, He A, et al
    Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/beta-catenin signaling pathway.
    PLoS One. 2017;12:e0186868.
    PubMed     Text format     Abstract available

  33. ASKMYR M, von Palffy S, Hansen N, Landberg N, et al
    Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells.
    PLoS One. 2017;12:e0186035.
    PubMed     Text format     Abstract available

  34. MEHANNA P, Gagne V, Lajoie M, Spinella JF, et al
    Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines.
    PLoS One. 2017;12:e0184365.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: